Literature DB >> 10735328

Relapse of depression after ECT: a review.

L N Bourgon1, C H Kellner.   

Abstract

Relapse of severe depression after successful treatment with electroconvulsive therapy (ECT) continues to be a major problem. We review the literature on relapse after ECT and factors that predict relapse. Early studies showed that the relapse rate was approximately 50% without follow-up treatment and that the majority of these relapses occurred in the first 6 months. More recent studies have found even higher rates in delusional depression and possibly in "double depression." Studies of biological markers as predictors of relapse were examined. Six of nine studies of the dexamethasone suppression test and one study of cortisol hypersecretion show that post-ECT nonsuppressors are at higher risk; although insensitive for diagnostic purposes, this test may be useful, when persistently abnormal, as a predictor of relapse. Studies of the thyrotropin-releasing hormone stimulation test and shortened rapid eye movement sleep latency are inconclusive. Medication resistance pre-ECT has been shown to predict relapse in two studies and highlights the need for more aggressive and effective treatment in this group. Further research into the prediction and prevention of depressive relapse after ECT is needed, and the field anxiously awaits current trials comparing ECT with combination lithium and nortriptyline.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10735328     DOI: 10.1097/00124509-200003000-00003

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  10 in total

1.  Sleep Disturbances in Pediatric Depression.

Authors:  Uma Rao
Journal:  Asian J Psychiatr       Date:  2011-12

2.  Acute relapse after successful vagus nerve stimulation therapy: a case report of last-resort ECT treatment.

Authors:  Liesbeth Santermans; Nathalie Vanderbruggen; Chris Baeken
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

3.  Electroconvulsive therapy: a life course approach for recurrent depressive disorder.

Authors:  Sarah Carney; Musa Basseer Sami; Victoria Clark; Kompancariel Kuruvilla Kuruvilla
Journal:  BMJ Case Rep       Date:  2015-05-24

4.  Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis.

Authors:  J E J Buckman; A Underwood; K Clarke; R Saunders; S D Hollon; P Fearon; S Pilling
Journal:  Clin Psychol Rev       Date:  2018-07-29

Review 5.  Electroconvulsive therapy: Part II: a biopsychosocial perspective.

Authors:  Nancy A Payne; Joan Prudic
Journal:  J Psychiatr Pract       Date:  2009-09       Impact factor: 1.325

6.  Electroconvulsive Therapy Hasn't Negative Effects on Short-Term Memory Function, as Assessed Using a Bedside Hand-Held Device.

Authors:  Helge H O Müller; Mareen Reike; Simon Grosse-Holz; Mareike Röther; Caroline Lücke; Alexandra Philipsen; Johannes Kornhuber; Teja W Grömer
Journal:  Ment Illn       Date:  2017-06-28

7.  Electroconvulsive Treatment: Hypotheses about Mechanisms of Action.

Authors:  Roar Fosse; John Read
Journal:  Front Psychiatry       Date:  2013-08-27       Impact factor: 4.157

8.  Possible Association between Serum Matrix Metalloproteinase-9 (MMP-9) Levels and Relapse in Depressed Patients following Electroconvulsive Therapy (ECT).

Authors:  Chiyo Shibasaki; Kei Itagaki; Hiromi Abe; Naoto Kajitani; Mami Okada-Tsuchioka; Minoru Takebayashi
Journal:  Int J Neuropsychopharmacol       Date:  2018-03-01       Impact factor: 5.176

9.  Combination of Electroconvulsive Therapy and Clozapine in Treatment-Resistant Schizophrenia.

Authors:  Jung Hyun Kim; Tak Youn; Jun Gwon Choi; Seong Hoon Jeong; Hee Yeon Jung; Yong Sik Kim; In Won Chung
Journal:  Psychiatry Investig       Date:  2018-08-09       Impact factor: 2.505

10.  Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.

Authors:  Sanne Y Smith-Apeldoorn; Jolien K E Veraart; Jeanine Kamphuis; Antoinette D I van Asselt; Daan J Touw; Marije Aan Het Rot; Robert A Schoevers
Journal:  BMC Psychiatry       Date:  2019-11-29       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.